Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CCNK | O75909 | 2/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29691288 | 1.00 | LMNA (0.53) | LMNAKMT2AGRNSORT1NAMPT | |
| Hydrochloric Acid SCHEMBL5012063 | 0.98 | LMNA (0.51) | LMNAKMT2AGRNSORT1NAMPT | |
| SCHEMBL4178530 | 0.83 | LMNA (0.53) | LMNAKMT2AGRNSORT1NAMPT | |
| SCHEMBL14638384 | 0.83 | LMNA (0.56) | LMNAKMT2AGRNSORT1NAMPT | |
| SCHEMBL18338880 | 0.83 | LMNA (0.53) | LMNAKMT2AGRNSORT1NAMPT | |
| SCHEMBL30046017 | 0.83 | LMNA (0.56) | LMNAKMT2AGRNSORT1NAMPT | |
| SCHEMBL1599534 | 0.83 | LMNA (0.56) | LMNAKMT2AGRNSORT1NAMPT | |
| SCHEMBL951325 | 0.83 | LMNA (0.53) | LMNAKMT2AGRNSORT1NAMPT | |
| SCHEMBL1598470 | 0.83 | LMNA (0.49) | LMNAKMT2AGRNSORT1NAMPT | |
| Hydrochloric Acid SCHEMBL18338785 | 0.82 | LMNA (0.51) | LMNAKMT2AGRNSORT1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-115605477-B | Pyrazolo [1,5-a ] pyridine derivative, preparation method, composition and application thereof | 深圳众格生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023169453-A1 | HETEROAROMATIC RING-CONTAINING ALKYNYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2023-09-14 | — | — | WO | disclosed |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| EP-4141003-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2023-03-01 | — | — | EP | disclosed |
| CN-115605477-A | Pyrazolo [1,5-a ] pyridine derivative and preparation method, composition and application thereof | 深圳众格生物科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-109206550-B | Hybrid supermolecule dynamic polymer | 厦门天策材料科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-9649309-B2 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649309-B2 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150322019-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2015-11-12 | — | — | US | disclosed |
| US-20150322019-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2015-11-12 | — | — | US | disclosed |
| US-20150322019-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2015-11-12 | — | — | US | disclosed |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| WO-2015157127-A1 | THERAPUETIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| WO-2015157127-A1 | THERAPUETIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322019-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TYMP, TYMS, DPYD | LMNA 2750/4885KMT2A 1815/4885GRN 1775/4885 |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | MERTK, FLT3, TK1 | LMNA 4217/4885KMT2A 1609/4885GRN 3831/4885 |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | LMNA 2181/4885KMT2A 2234/4885GRN 3675/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | LMNA 2181/4885KMT2A 2234/4885GRN 3675/4885 |
| US-20230159523-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NCOA4, CCDC47, CCDC6 | LMNA 3326/4885KMT2A 1723/4885GRN 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.